NASDAQ
1.25USD
-0.07 (-4.94%)
We have scored 6 news catalysts on Vivani Medical, Inc. (VANI) over the past 12 months. The biggest single-day move next to one of them came Oct 3, 2025, when VANI closed −8.5%: “Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off”. Coverage across the window leans positive (average ticker sentiment +0.25). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
107.8M
P/E
—
EPS
—
Beta
3.28
52W range
0.923-1.92
Day range
1.25–1.33
Open
1.33
Prev close
1.31
Volume
254.3K
Avg volume
389K
Dividend
0.00
IPO
2014-11-19
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Vivani Medical, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VANI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
